CTI BioPharma (CTIC) Misses Q4 EPS by 9c, Offers Guidance

CTI BioPharma (NASDAQ: CTIC) reported Q4 EPS of ($0.27), $0.09 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $17.8 million, may not compare to the consensus estimate of $2.48 million.

CTI BioPharma sees FY2015 revenue of $50-55 million, versus the consensus of $50.17 million. CTI BioPharma expects that non-GAAP operating loss for 2015 will be approximately $75 million to $85 million, which excludes non-cash share-based compensation expense.

For earnings history and earnings-related data on CTI BioPharma (CTIC) click here.

You May Also Be Interested In

• Calix, Inc. (CALX) Tops Q3 EPS by 3c; offers guidance
• ONE Gas (OGS) Tops Q3 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
• Pampa Energía S.A. (PAM) Misses Q3 EPS by 240c